Tonix Pharmaceuticals prices $15,000,000 public offering
Tonix announced pricing of an underwritten public offering with gross proceeds of $15,000,000. The Company expects to use the net proceeds from this offering to help fund a new Phase 3 study using a modified trial design for its lead product candidate, TNX-102 SL. December 07, 2018